RxDoctor Payments Data

Gabriel Szentpaly, MD

Internal Medicine · Cambridge, MANPI 1942233119

Payments from drug & device makers

$1,565in general payments, 2019–2025

Across 77 payments — averaging $20.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$209
  • AstraZeneca$144
  • Amgen$133
  • Boehringer Ingelheim$118
  • Takeda Pharmaceuticals U.S.A., Inc.$118
  • Novo Nordisk$104
  • plus $738 from 17 others

What the payments were for

  • Food & beverage$1,54699%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,565 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$137,585
Medicare patients
313
Services billed
1,957

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban77$85,075
JardianceEmpagliflozin41$58,552
TrulicityDulaglutide40$36,770
XareltoRivaroxaban21$26,098
MounjaroTirzepatide11$12,219
FarxigaDapagliflozin Propanediol11$10,245
Atorvastatin Calcium630$9,483
Breo ElliptaFluticasone/Vilanterol21$8,446
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,887
Valsartan159$7,493
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$7,392
Arnuity ElliptaFluticasone Furoate18$5,968
Pravastatin Sodium205$5,017
Metoprolol Succinate235$4,362
Rosuvastatin Calcium117$4,267

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$209$85,07577 claims
Boehringer IngelheimJardiance$118$58,55241 claims
Lilly USA, LLCTrulicity, Mounjaro$24$48,99051 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta$31$33,41381 claims
Johnson & JohnsonXarelto$83$26,09821 claims
AstraZenecaFarxiga$144$10,24511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Cambridge

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →